A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.
Exploring the companies and themes that make up this emerging and exciting new sector
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.